- Home
- MITQ vs APM Comparison
MITQ vs APM Comparison
Compare MITQ & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MITQ | APM |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 8.0M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MITQ | APM |
|---|---|---|
| Price | $0.62 | $0.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.6K | ★ 47.9K |
| Earning Date | 05-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $20,139,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $60.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.65 |
| 52 Week High | $1.66 | $4.47 |
Technical Indicators
Market Signals| Indicator | MITQ | APM |
|---|---|---|
| Relative Strength Index (RSI) | 33.07 | 40.06 |
| Support Level | $0.58 | $0.65 |
| Resistance Level | $0.79 | $0.86 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 13.12 | 53.57 |
Price Performance
Historical ComparisonAbout MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.